G-15: Selective GPR30 Antagonist for Precision Estrogen Signaling Research

Executive Summary: G-15 (CAS 1161002-05-6) is a highly selective antagonist for G protein-coupled estrogen receptor 30 (GPR30), exhibiting minimal cross-reactivity with classical estrogen receptors ERα or ERβ (Peng Wang et al. 2021, doi). It inhibits GPR30-mediated calcium mobilization and PI3K/Akt activation with a binding affinity (Ki) near 20 nM (APExBIO). In vitro, G-15 reverses G-1-induced cell proliferation and downstream signaling in SKBr3 cells at IC50 ≈185 nM (APExBIO). In vivo, subcutaneous administration impairs estrogen-dependent spatial learning in rat models, demonstrating research utility in neurobiology and immunology (Peng Wang et al. 2021). The compound is applied widely for dissecting rapid, non-genomic estrogen actions in cancer, neurodegenerative, and immune contexts (see also).

Biological Rationale

Estrogen signaling is mediated by both nuclear receptors (ERα, ERβ) and the membrane-localized GPR30. GPR30, a G protein-coupled estrogen receptor, triggers rapid, non-genomic signaling upon binding ligands such as estradiol. This pathway regulates intracellular calcium, PI3K/Akt activity, and immune cell function (Peng Wang et al. 2021). Selective modulation of GPR30 is crucial for dissecting the specific roles of membrane-initiated estrogen signaling, especially in systems where classical ERs are expressed concurrently (Decoding GPR30). G-15 enables precise inhibition of these pathways, allowing researchers to identify GPR30-dependent versus -independent mechanisms.

Mechanism of Action of G-15

G-15 binds to GPR30 with a Ki of approximately 20 nM, acting as a competitive antagonist. It does not significantly interact with ERα or ERβ, even at concentrations exceeding those required for GPR30 blockade (APExBIO). Mechanistically, G-15 inhibits estrogen- or G-1-induced intracellular calcium mobilization, suppresses PI3K activation, and prevents downstream Akt phosphorylation in GPR30-expressing cells. In SKBr3 breast cancer cells, G-15 inhibits G-1-stimulated calcium mobilization with an IC50 of ~185 nM. This blockade results in reversal of G-1-induced cell proliferation. In vivo, G-15 impairs spatial learning in ovariectomized rats in a dose-dependent manner, implicating GPR30 in neurocognitive estrogen effects (Peng Wang et al. 2021).

Evidence & Benchmarks

• G-15 (5 or 10 μg/day, subcutaneous) abolishes estradiol-induced normalization of CD4+ T lymphocyte proliferation in hemorrhagic shock rat models (Peng Wang et al. 2021).
• In SKBr3 cells, G-15 inhibits G-1-induced intracellular calcium mobilization with an IC50 of 185 nM (APExBIO).
• G-15 does not block ERα or ERβ, confirmed by lack of effect on ERα/ERβ-driven responses even at high micromolar concentrations (APExBIO).
• G-15 blocks PI3K/Akt pathway activation downstream of GPR30 in cellular models (America Peptide).
• G-15 impairs spatial learning acquisition in ovariectomized female rats, demonstrating in vivo relevance of GPR30 antagonism (Peng Wang et al. 2021).

This article extends previous discussion in "G-15: Selective GPR30 Antagonist for Precision Estrogen Signaling" by providing updated benchmarks and workflow integration strategies.

Applications, Limits & Misconceptions

G-15 is utilized in cancer biology, neurobiology, and immunology to dissect GPR30-specific estrogen actions (G-15 unlocks GPR30 inhibition). It is particularly valuable for distinguishing rapid, non-genomic estrogen signaling from classical ER-mediated effects. Common experimental applications include:

• Cell-based assays to probe GPR30-mediated calcium or PI3K/Akt signaling.
• Animal models of neurodegenerative disease or immune modulation.
• Dissecting proliferative effects of estrogens in cancer cell lines.
• Validation of GPR30 as a therapeutic target in translational research.

Compared to Decoding GPR30, this review incorporates new in vivo benchmarks and addresses solution preparation and storage best practices.

Common Pitfalls or Misconceptions

• G-15 is not effective for blocking classical ERα or ERβ; it is selective for GPR30 only.
• G-15 is insoluble in water and ethanol; use DMSO for stock solutions at ≥37 mg/mL.
• Long-term storage of G-15 solutions is not advised; prepare fresh aliquots as needed and warm/sonicate to improve solubility.
• G-15 does not act as an agonist; it is a pure antagonist at GPR30.
• Not all estrogen signaling is mediated via GPR30; use parallel controls to confirm pathway specificity.

Workflow Integration & Parameters

For cell-based assays, prepare G-15 stock in DMSO at >10 mM, dilute as appropriate in culture media. For in vivo work, dissolve in DMSO and dilute to the desired concentration for subcutaneous injection (e.g., 5 or 10 μg/day per rat). Recommended storage is at -20°C for the solid compound; avoid freeze-thaw cycles. Solutions should be freshly prepared; warming and ultrasonic treatment can enhance solubility (APExBIO). Molecular formula: C19H16BrNO2, molecular weight: 370.24. Refer to the G-15 product page for full technical details and safety data.

This article clarifies workflow integration beyond what is covered in "Unlocking the Next Frontier in Estrogen Signaling", which focuses on translational research applications.

Conclusion & Outlook

G-15, provided by APExBIO, is the gold standard for selective GPR30 antagonism in estrogen signaling research. Its robust specificity and validated benchmarks enable researchers to dissect rapid, membrane-initiated estrogen pathways in cancer, neurobiology, and immunology. Future research leveraging G-15 is poised to clarify mechanistic roles for GPR30 in disease and inform therapeutic strategies targeting non-genomic estrogen effects. For comprehensive mechanistic and translational insight, see related content such as G-15: Selective GPR30 Antagonist.